Virios Therapeutics, Inc.

  • About Virios
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Corporate Presentation
  • Target Diseases
    • Fibromyalgia
    • Long Covid
    • Blog
  • Pipeline
    • Pipeline
    • Presentations and Publications
  • Investors
  • News
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News
    • Press Releases
    • Email Alerts
  • Events & Presentations
    • Events
    • Presentations
    • Shareholder Letters
    • Meeting
  • Governance
    • Overview
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial & Stock Info
    • Overview
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Resources
    • Overview
    • IR Contacts
    • FAQ
    • Email Alerts
  • News

  • Press Releases
  • Email Alerts
Jun 01, 2022 7:05am EDT

Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia

May 12, 2022 7:05am EDT

Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 05, 2022 7:05am EDT

Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022

Apr 28, 2022 7:05am EDT

Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b “FORTRESS” Clinical Trial for Fibromyalgia

Mar 17, 2022 7:05am EDT

Virios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Mar 10, 2022 7:05am EST

Virios Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thursday, March 17, 2022

Mar 08, 2022 4:05pm EST

Virios Therapeutics to Present at the 34th Annual Roth Conference on Monday, March 14, 2022

Feb 28, 2022 7:05am EST

Virios Therapeutics Announces Research Collaboration Exploring the Potential of Combination Antiviral Therapy for Treating Long COVID

Jan 04, 2022 4:05pm EST

Virios Therapeutics to Present at the Virtual H.C. Wainwright BioConnect Conference

Dec 01, 2021 7:05am EST

Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia

  • 1
  • 2
  • 3
  • 4
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

© 2022 Virios Therapeutics, Inc.           Terms and Conditions Privacy Policy Social Media Guidelines